Pityriasis (Tinea) versicolor is a fungal infection caused by Malassezia furfur. It is benign, superficial, and localized to the stratum corneum.
It may present as chronic or recurrent infection and may occur in healthy individuals.
It is more common in summer than winter months.
It presents with multiple well-demarcated macules or patches and finely scaled plaques with hypopigmentation or hyperpigmentation, hence the term "versicolor".
Lesions are usually found on the upper trunk, chest, back and shoulders, and may extend toward the neck, face and arms.
Ketoconazole is a vital treatment of pityriasis versicolor but is primarily used in cream form. This study has evaluated the safety and efficacy of ketoconazole 2% foam in the management of pityriasis versicolor.
Aspergillus colonization may lead to an increase in the risk of bronchiolitis obliterans syndrome. This study determined the impact of colonization of conidia Aspergillus species after post lung transplantation.
No standard currently exists for the growing number of patients with multidrug-resistant strains of Helicobacter pylori, but a recent study has shown the safety and reliability of a 12-day low-dose rifabutin/high-dose proton pump inhibitor (PPI) regimen in patients infected with triple-resistant strains.
Daily administration of two probiotic strains, Bifidobacterium animalis subsp lactis and Lactobacillus rhamnosus, does not appear to be effective in the prevention of respiratory or gastrointestinal infections in infants, as shown in the ProbiComp* study.
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.